OBR – News, Perspective, Catalyst

Today's Oncology News

Opt In Search Archives

FDA Approves First Therapy To Treat Patients With Rare ...

(FDA.gov) Nov 8, 2019 - Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of an...

Celgene's Drug For Anemia In Beta Thalassemia Priced At...

(Reuters) Nov 8, 2019 - Celgene Corp’s treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,...

U.S. Food and Drug Administration Accepts for Priority ...

(BMS) Nov 11, 2019 - The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication. Bristol-Myers ...

ASLAN Pharmaceuticals Announces Topline Results From Tr...

(ASLAN) Nov 11, 2019 - The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour o...

Featured Content

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Edward Garon, MD, Associate Professor of Medicine, Geffen School of Medicine at UCLA, discuss lung cancer highlights from ASCO 2019.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss HCC highlights from ASCO 2019.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Scott Kopetz, MD, PhD, FACP, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson, provide CRC clinical update post World GI '19.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss ovarian cancer clinical updates from ESMO 19

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Marwan Fakih, MD, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss colorectal cancer clinical updates from ESMO 19

Artificial intelligence (AI) has the potential to identify patients with cancer at high risk of unplanned utilization of acute care, a critical healthcare cost driver. OBR spoke with Cardinal Health’s Amy Valley, PharmD, on the opportunities and obstacles to implementing AI in identification of these high-risk patients.

Patient-reported outcomes (PROs) monitoring has been shown to have multiple benefits for cancer patients, while also representing an important tool for providers in implementing value-based care. We look at some of the steps needed to integrate PROs effectively and seamlessly into the electronic workflow and routine cancer care.

Podcasts

Colorectal Cancer – Marwan Fakih, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical update

00:00

Listen on
Apple Podcasts

Listen on
Google Play

Listen on
Spotify

Title

Released

Ovarian Cancer – Bradley Monk, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical update

10/10/19

Colorectal Cancer (CRC) - Scott Kopetz, MD, and Robert Figlin, MD, provide post World GI '19 clinical update

07/30/19

Hepatocellular carcinoma (HCC) - Daneng Li, MD and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

07/02/19

Breast Cancer – Neelima Denduluri, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

06/21/19

Expert Video Insights

Search by

Stephen Grubbs, MD, FASCO, shares a message to practices considering value-based contracting

Christopher J. Hoimes, MD, regarding the EV-103 study presented at ESMO 2019

OBR Green

View Archives

November 2019 Edition

Patient-reported outcomes (PROs) monitoring has been shown to have multiple benefits for cancer patients, while also representing an important tool for providers in implementing value-bas...

November 2019 Edition

Artificial intelligence (AI) has the potential to identify patients with cancer at high risk of unplanned utilization of acute care, a critical healthcare cost driver. OBR spoke with Card...

Blog

Third-Line Treatment in Metastatic Colorectal Cancer Po...

Oct 07, 2019

Targeted oral tyrosine kinase inhibitors (TKIs) have an established role in third-line treatment of metastatic colorectal cancer (mCRC), but an expert outlined an...

ESMO Opens with Survival Benefits from Long-Term Data i...

Sep 30, 2019

The 2019 European Society of Medical Oncology (ESMO) opened with a series of trials with positive overall survival (OS) data. Generally considered the gold standa...

Rapid Integration of Information Presented at 2019 ASCO...

Jul 15, 2019

Introduction OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in ...

OBR Tools

Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.

Learn More

The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.

Learn More

Oncology Events Calendar

November 14, 2019